Page 32 - Read Online

Page 12 of 12 Khan et al. J Cancer Metastasis Treat 2019;5:71 I http://dx.doi.org/10.20517/2394-4722.2019.017

Ann Intern Med 1975;83:654-6.
35. Mori T, Katayama Y, Kawamata T, Hirayama T. Improved efficiency of hypervolemic therapy with inhibition of natriuresis by
fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1999;91:947-52.
36. Lampl C, Yazdi K. Central pontine myelinolysis. Eur Neurol 2002;47:3-10.
37. Dokmak A, Madias NE. Hyponatremia and in-hospital falls and fractures in older adults. J Am Geriatr Soc 2019;67:1752-3.
38. Sterns RH. The management of symptomatic hyponatremia. Semin Nephrol 1990;10:503-14.
39. Adrogue HJ, Madias NE. Diagnosis and treatment of hyponatremia. Am J Kidney Dis 2014;64:681-4.
40. Sood L, Sterns RH, Hix JK, Silver SM, Chen L. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe
hyponatremia. Am J Kidney Dis 2013;61:571-8.
41. Gross PA, Wagner A, Decaux G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int 2011;80:594-600.
42. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with
euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf) 2008;69:159-68.
43. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for
hyponatremia. N Engl J Med 2006;355:2099-112.
44. Chiong JR, Kim S, Lin J, Christian R, Dasta JF. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction
among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ 2012;15:276-84.
45. Peri A. Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 2013;98:1321-32.
46. Khan MI, Dellinger RP, Waguespack SG. Electrolyte disturbances in critically Ill cancer patients: an endocrine perspective. J Intensive
Care Med 2018;33:147-58.